News NICE to reassess Pfizer blood cancer drug Company successfully appealed against rejection last summer
Views & Analysis UK life sciences: the impact of a cycle of affordability and... The changing landscape for drug pricing and some pointers for the UK life sciences sector.
News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
News Pfizer's Ibrance available across UK after thumbs up in Scot... Around 800 women have received the drug for free.
News NICE recommends Eisai's kidney cancer combination NICE has recommended Eisai’s Kisplyx (lenvatinib) in combination with Novartis’ Afinitor (everolimus) in kidney cancer after the company further dropped its price.
News Eisai: UK gives pharma a poor deal, may invest elsewhere Japanese pharma getting frustrated with NICE
News Aspen, Bambusa close IPOs as Corxel takes SPAC route Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
